Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.

ABSTRACT:

Objectives

To evaluate the extent to which patients with type 2 diabetes discontinue metformin therapy when initiating second-line treatment and factors associated with metformin discontinuation, using baseline data from the DISCOVER study programme.

Design

DISCOVER is a 3-year, prospective, observational study programme including data from 38 countries across 6 continents from 2014 to 2019.

Setting

Primary and secondary healthcare centres, hospitals and specialist diabetes centres in both urban and rural locations.

Participants

A total of 15 992 patients with type 2 diabetes initiating second-line glucose-lowering therapy.

Primary and secondary outcome measures

The proportion of patients who discontinued metformin as a second-line therapy and the factor

SUBMITTER: Khunti K 

PROVIDER: S-EPMC7462233 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature